Keywords: Eli Lilly, Solpura, Pancreatic, Cystic fibrosis, USA, FDA

US FDA calls for additional study on Lilly’s EPI drug candidate Solpura

Article | 18 April 2011

Print This

In what is a disappointment, but probably no surprise to US drug major Eli Lilly (NYSE: LLY), the company says ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in